[go: up one dir, main page]

AR111842A1 - Antagonistas de péptido pac1 - Google Patents

Antagonistas de péptido pac1

Info

Publication number
AR111842A1
AR111842A1 ARP180101446A ARP180101446A AR111842A1 AR 111842 A1 AR111842 A1 AR 111842A1 AR P180101446 A ARP180101446 A AR P180101446A AR P180101446 A ARP180101446 A AR P180101446A AR 111842 A1 AR111842 A1 AR 111842A1
Authority
AR
Argentina
Prior art keywords
amino acid
acid residue
absent
neutral
ala
Prior art date
Application number
ARP180101446A
Other languages
English (en)
Inventor
Leslie Miranda
Jason Long
Fang Hong
- Harrington Essa Hu Tsao
su Chong
Irwin Chen
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of AR111842A1 publication Critical patent/AR111842A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se brindan péptidos que se enlazan a PAC1 humano. Estos péptidos que son antagonistas de PAC1 son útiles en varios trastornos relacionados con PAC1, que incluye el tratamiento y/o la prevención de trastornos de cefalea, lo que incluye migraña, como ser migraña aguda. Reivindicación 1: Un péptido de fórmula (1), o una sal farmacéuticamente aceptable del mismo, X⁰X¹X²X³X⁴X⁵X⁶X⁷X⁸X⁹X¹⁰X¹¹X¹²X¹³X¹⁴X¹⁵X¹⁶X¹⁷X¹⁸X¹⁹X²⁰X²¹X²²X²³X²⁴X²⁵X²⁶X²⁷X²⁸X²⁹X³⁰X³¹X³²X³³X³⁴X³⁵X³⁶X³⁷X³⁸X³⁹X⁴⁰X⁴¹X⁴²X⁴³X⁴⁴ (1), donde X⁰ es Gly, Ser, Gly-Ser-, Ala, Met, Gly-Met-, [Pra], o está ausente, X¹ es Cys si X⁵ es Cys o X¹ es Ser si X⁵ es Ser, Thr, o está ausente, X² es Asp, Glu, o un residuo ácido de aminoácido, o está ausente, X³ es Ala, Pro, Ser, [Aib], o un residuo hidrófobo de aminoácido, o está ausente, X⁴ es Thr, Ser, Val, Tyr, o un residuo neutral, hidrófilo o hidrófobo de aminoácido, o está ausente, X⁵ es Cys si X¹ es Cys o X⁵ es Ser si X¹ es Ser, o está ausente, X⁶ es Lys, [Cit], His, Arg, u otro residuo básico de aminoácido o Gln, Asn, Phe u otro residuo neutral, de aminoácido o Glu u otro residuo ácido de aminoácido, o está ausente, X⁷ es Phe, Tyr, His, o un residuo neutral o hidrófobo de aminoácido, o está ausente, X⁸ es Lys, Arg, o un residuo básico de aminoácido, o está ausente, X⁹ es Lys, Arg, o un residuo básico de aminoácido, o está ausente, X¹⁰ es Ala, Cys, Gly, Leu, Gln, Val, o un residuo neutral de aminoácido, o está ausente, X¹¹ es Ile, Leu, Met, [Aib], o un residuo hidrófobo de aminoácido, o está ausente, X¹² es Asp, Glu, o un residuo ácido de aminoácido, o Ala, Val u otro residuo neural de aminoácido, o está ausente, X¹³ es Asp, Glu, o un ácido, o Ala, Val, [Aib], u otro residuo neutral de aminoácido, o Lys, o está ausente, X¹⁴ es Cys, Ile, Met, Ser, Trp, o está ausente, X¹⁵ es Gln, Ala, Phe, Ile, Leu, Met, Ser, Val, Trp, Tyr u otro aminoácido neutral, o Asp, [Cit], u otro residuo neutral o ácido de aminoácido, o His, Lys u otro residuo básico de aminoácido, o está ausente, X¹⁶ es Lys, Arg, His, u otro residuo básico de aminoácido o Phe, Ile, Leu, [Aib], Gln, Met, Thr, Val, Gly, Asn, [Pra], Trp, Tyr u otro residuo neutral o [hGlu] ácido de aminoácido, o está ausente, X¹⁷ es Ala, Gln, [Aib], Phe, Ile, Leu, Ser, Val, Trp, Tyr, Thr u otro residuo neutral de aminoácido, o [Cit], Lys, Arg, u otro residuo básico de aminoácido o Asp, u otro residuo ácido de aminoácido o está ausente, X¹⁸ es Ala, Leu, [Aib], [Pra], u otro residuo neutral de aminoácido, o Glu u otro residuo ácido de aminoácido o Lys, u otro residuo básico de aminoácido, o está ausente, X¹⁹ es His u otro residuo básico de aminoácido o Ala, Phe, Ile, Leu, Met, Gln, Ser, Val, Trp, Tyr, [Aib], o u otro residuo neutral o hidrófobo de aminoácido, o Lys, Arg u otro residuo básico de aminoácido, o está ausente, X²⁰ es Ala, [Aib], Tyr, u otro residuo neutral o hidrófobo de aminoácido, o His u otro residuo básico de aminoácido, o está ausente, X²¹ es Ala, Met, Ser, Val, [Aib], o un residuo neutral de aminoácido, o está ausente, X²² es Asn, His, Gln, u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X²³ es Gly, Val, Thr, u otro residuo neutral de aminoácido, o Glu u otro residuo ácido de aminoácido o Lys, u otro residuo básico de aminoácido, o está ausente, X²⁴ está ausente, es Pro, [Pip], [Sar], [Hyp], [DHP] o un residuo neutral de aminoácido, o Arg u otro residuo básico de aminoácido, X²⁵ está ausente, es Ala, Gly, Tyr, [Pra], o un residuo neutral de aminoácido, X²⁶ está ausente, es Asn, Gln, o un residuo neutral de aminoácido, o Leu-Gln-Thr-Ser-Val-, X²⁷ es Ala, Gly, Ser, [Aib], u otro residuo neutral o hidrófilo de aminoácido, o Asp u otro residuo ácido de aminoácido, o está ausente, X²⁸ está ausente, es Val, Thr, u otro residuo neutral o hidrófilo de aminoácido, o Lys u otro residuo básico de aminoácido, X²⁹ está ausente, es APhe, Trp, Tyr, [Aib], o un residuo neutral o hidrófobo de aminoácido, X³⁰ es Lys, [Aib], Ala, [d-Ala], u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³¹ es Glu, [Aib], Ala, Ser, Thr, Val, Leu, u otro residuo ácido o neutral de aminoácido, o Lys u otro residuo básico de aminoácido, o está ausente, X³² es Cys, Arg, Leu, Ser, o está ausente, X³³ es la, Phe, Ile, Leu, Ser, Val, [SeMet], Met, [Nle], Cys, u otro residuo hidrófobo de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³⁴ es Lys, [Aib], Ala, Leu, Val, u otro residuo básico o neutral de aminoácido, o Glu u otro residuo ácido de aminoácido, o está ausente, X³⁵ es Gln, Phe, Glu, Asn, Thr, [Aib], Ala, Pro, Cys, u otro residuo ácido o neutral de aminoácido, o Arg u otro residuo básico de aminoácido, o está ausente, X³⁶ es Lys, [d-Lys], [Orn], Glu, Gly, Gln, His, Ala, [Aib], [NMeLys], Cys, Arg, Leu, o un residuo básico o neutral de aminoácido, o está ausente, X³⁷ es Lys, Ala, Gln, [Aib], Phe, Arg, o un residuo básico o neutral de aminoácido, o está ausente, X³⁸ está ausente, es Lys, Ala, [Aib], Glu, [Orn], Gln, Gly, [d-Lys], [NMeLys], Phe, Leu, Asn, Arg, Thr, o un residuo ácido básico o neutral de aminoácido, X³⁹ está ausente, es Glu, Ala, [Aib], Leu, Val, u otro residuo ácido o neutral de aminoácido, o Arg u otro residuo básico de aminoácido, X⁴⁰ está ausente, es Phe, [AMEF], Trp,[d-Phe], [hPhe], Tyr, [Aib], [pI-Pheo], o un residuo neutral o hidrófobo de aminoácido, o Glu u otro residuo ácido de aminoácido, X⁴¹ está ausente, es Lys, [NMeLys],[d-Lys], Gln, Glu, His, Ala, [Aib], Leu, Arg, o un residuo básico, o ácido o neutral de aminoácido, X⁴² está ausente, es Ala, Glu, [Aib], Pro, Cys, o un residuo ácido o neutral de aminoácido, X⁴³ está ausente, es Gly, Glu, Ala, [Aib], Asn, Gln, Trp, Cys, u otro residuo neutral o ácido de aminoácido, o His, Arg cu otro residuo básico de aminoácido, X⁴⁴ está ausente, es Lys, His, [d-Lys], [Orn], Ala, Phe, Asn, Gln, Arg, Trp, Tyr un residuo básico o neutral de aminoácido, o fragmentos -Gly-Ser, -Gly-Gly-Gly-Ser, -His-His-His-His-His, o-His- His-His-His-His-His, o Glu u otro aminoácido ácido, donde 11 residuos de aminoácido pueden estar ausentes al mismo tiempo, donde X¹ y X⁵ y puede, opcionalmente, formar enlaces de disulfuro, donde X¹⁴ y X³² y puede, opcionalmente, formar enlaces de disulfuro, donde el residuo del extremo amino pueden estar opcionalmente acetilados y el residuo de extremo carboxi puede estar opcionalmente amidada.
ARP180101446A 2017-06-02 2018-05-31 Antagonistas de péptido pac1 AR111842A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762514440P 2017-06-02 2017-06-02

Publications (1)

Publication Number Publication Date
AR111842A1 true AR111842A1 (es) 2019-08-21

Family

ID=62685214

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101446A AR111842A1 (es) 2017-06-02 2018-05-31 Antagonistas de péptido pac1

Country Status (10)

Country Link
US (1) US11643440B2 (es)
EP (1) EP3630147A2 (es)
JP (1) JP7195281B2 (es)
AR (1) AR111842A1 (es)
AU (1) AU2018275270B2 (es)
CA (1) CA3065115A1 (es)
MA (1) MA48780A (es)
TW (1) TW201920235A (es)
UY (1) UY37753A (es)
WO (1) WO2018222991A2 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7756001B2 (ja) 2019-06-28 2025-10-17 アムジエン・インコーポレーテツド 抗cgrp受容体/抗pac1受容体二重特異性抗原結合タンパク質

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
NO812612L (no) 1980-08-06 1982-02-08 Ferring Pharma Ltd Enzym-inhibitorer.
US4612132A (en) 1984-07-20 1986-09-16 Chevron Research Company Modified succinimides
US5397772A (en) 1989-06-29 1995-03-14 The President And Fellows Of Harvard College Vasodilatory peptides from the salivary gland of the sand fly Lutzomyia longipalpis
US5683888A (en) 1989-07-22 1997-11-04 University Of Wales College Of Medicine Modified bioluminescent proteins and their use
US5292658A (en) 1989-12-29 1994-03-08 University Of Georgia Research Foundation, Inc. Boyd Graduate Studies Research Center Cloning and expressions of Renilla luciferase
US5331573A (en) 1990-12-14 1994-07-19 Balaji Vitukudi N Method of design of compounds that mimic conformational features of selected peptides
DK0575319T3 (da) 1991-03-11 2000-07-10 Univ Georgia Res Found Kloning og ekspression af Renilla-luciferase
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5480864A (en) 1993-08-06 1996-01-02 Shiseido Co., Ltd. Modified maxadilan protein, its preparation and use, and DNA encoding the protein
WO1995007463A1 (en) 1993-09-10 1995-03-16 The Trustees Of Columbia University In The City Of New York Uses of green fluorescent protein
WO1995021191A1 (en) 1994-02-04 1995-08-10 William Ward Bioluminescent indicator based upon the expression of a gene for a modified green-fluorescent protein
US5463564A (en) 1994-09-16 1995-10-31 3-Dimensional Pharmaceuticals, Inc. System and method of automatically generating chemical compounds with desired properties
US5777079A (en) 1994-11-10 1998-07-07 The Regents Of The University Of California Modified green fluorescent proteins
JPH08333392A (ja) * 1995-06-05 1996-12-17 Shiseido Co Ltd 生理活性ポリペプチド類
US6462016B1 (en) * 1995-10-06 2002-10-08 Shiseido Company, Ltd. Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
US5874304A (en) 1996-01-18 1999-02-23 University Of Florida Research Foundation, Inc. Humanized green fluorescent protein genes and methods
US5804387A (en) 1996-02-01 1998-09-08 The Board Of Trustees Of The Leland Stanford Junior University FACS-optimized mutants of the green fluorescent protein (GFP)
US5876995A (en) 1996-02-06 1999-03-02 Bryan; Bruce Bioluminescent novelty items
US5880972A (en) 1996-02-26 1999-03-09 Pharmacopeia, Inc. Method and apparatus for generating and representing combinatorial chemistry libraries
US6017533A (en) 1996-04-25 2000-01-25 Shiseido Company, Ltd. Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
US5925558A (en) 1996-07-16 1999-07-20 The Regents Of The University Of California Assays for protein kinases using fluorescent protein substrates
US5976796A (en) 1996-10-04 1999-11-02 Loma Linda University Construction and expression of renilla luciferase and green fluorescent protein fusion genes
US6458547B1 (en) 1996-12-12 2002-10-01 Prolume, Ltd. Apparatus and method for detecting and identifying infectious agents
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6232107B1 (en) 1998-03-27 2001-05-15 Bruce J. Bryan Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items
US20020182729A1 (en) * 2001-01-11 2002-12-05 Dicicco-Bloom Emanuel Pituitary adenylate cyclase-activating polypeptide (PACAP) is an anti-mitogenic signal for selected neuronal precursors in vivo
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2003092716A2 (en) 2002-05-03 2003-11-13 Neuronova Ab Therapeutic use of pacap, maxadilan, pacap receptor agonist and/or adcyap1r1 in the treatment of cns disorders
BR0315872A (pt) 2002-10-29 2006-07-18 Us Gov Health & Human Serv Polipeptìdeos de lutzomyia longipalpis e processos de utilização e método de uso
CN101125881A (zh) * 2007-07-20 2008-02-20 暨南大学 重组pac1受体结抗剂d(25-44)rmmax及其表达方法与应用
WO2009033489A2 (en) * 2007-09-11 2009-03-19 Glostrup Hospital Selective pacl inhibitors for use in the treatment of migraine and headaches
CN103768588A (zh) 2008-05-08 2014-05-07 梅里亚有限公司 使用白蛉唾液免疫原的利什曼原虫疫苗
EP2313783A2 (en) 2008-07-18 2011-04-27 Galderma Research & Development Pacap signaling pathway modulators for treating inflammatory skin diseases with a neurogenic component, and more particularly rosacea and composition containing them
WO2010078469A2 (en) 2008-12-31 2010-07-08 The Usa As Represented By The Secretary, Department Of Health And Human Services Sand fly salivary proteins as novel factor xa inhibitors and methods of use
JP5447784B2 (ja) 2009-03-12 2014-03-19 国立大学法人 鹿児島大学 マキサディランの部分ペプチドを含む神経因性疼痛の治療剤
CA2797033C (en) 2010-04-22 2021-10-19 Longevity Biotech, Inc. Highly active polypeptides and methods of making and using the same

Also Published As

Publication number Publication date
UY37753A (es) 2018-11-30
US20210395313A1 (en) 2021-12-23
JP7195281B2 (ja) 2022-12-23
MA48780A (fr) 2020-04-08
AU2018275270B2 (en) 2024-06-06
EP3630147A2 (en) 2020-04-08
AU2018275270A1 (en) 2019-12-12
TW201920235A (zh) 2019-06-01
CA3065115A1 (en) 2018-12-06
WO2018222991A3 (en) 2019-01-31
JP2020522476A (ja) 2020-07-30
WO2018222991A2 (en) 2018-12-06
US11643440B2 (en) 2023-05-09

Similar Documents

Publication Publication Date Title
AR096162A1 (es) Péptidos terapéuticos
AR096927A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.7
AR064555A1 (es) Peptido wt1 restringido a hla-a*1101 y composicion farmaceutica que comprende el mismo
EP2214693B1 (en) Use of melanocortins to treat insulin sensitivity
US20170240595A1 (en) Melanocortin Receptor Ligands
JPH08510205A (ja) Yyペプチドのアナログとその用途
AR088413A1 (es) INHIBIDORES POTENTES Y SELECTIVOS DE NaV1.3 Y NaV1.7
WO2010111617A4 (en) Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use
ME03709B (me) Fuzijski proteini
JP2016512255A (ja) インスリン‐インクレチン複合物
IE57774B1 (en) Grf analogs
RU2017119773A (ru) Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение
AU2012210565B2 (en) Human lactoferrin derived peptides and there use
DE60318547T2 (de) Agonisten des corticotropin-freisetzenden faktor rezeptors 2
EP0352014A3 (en) Cyclic grf analogs
WO2012174397A3 (en) Anti-inflammatory pharmaceutical products
JP2017502003A5 (es)
AU2006269321A1 (en) Ligands of melanocortin receptors
AU2012210565A1 (en) Human lactoferrin derived peptides and there use
JP2017505772A5 (es)
AR111842A1 (es) Antagonistas de péptido pac1
KR930701486A (ko) Crf (씨이 알 에프) 유사체
AU2010216383B2 (en) Analogues of neuropeptide Y having at least one synthetic amino acid substitution
Laurent et al. A comparison of the leech Theromyzon tessulatum angiotensin I-like molecule with forms of vertebrate angiotensinogens: a hormonal system conserved in the course of evolution
Gagnon et al. Primary structure of the A chain of human complement-classical-pathway enzyme C1r. N-terminal sequences and alignment of autolytic fragments and CNBr-cleavage peptides

Legal Events

Date Code Title Description
FB Suspension of granting procedure